What Changed When the TGA Down-Scheduled Psilocybin in 2023, and What Does That Actually Mean for Patients?
On July 1, 2023, Australia made history. The Therapeutic Goods Administration (TGA) down-scheduled psilocybin from a Schedule 9 (Prohibited Substance) to a Schedule 8 (Controlled Drug) medicine for the specific treatment of treatment-resistant depression (TRD) . This made Australia the first country in the world to recognise psilocybin as a legitimate medicine within a formal national healthcare framework . Nevertheless, the change has generated significant debate and left many patients wondering what it actually means for them. This guide breaks down the change, its practical implications, and the current realities of accessing this treatment.
What Actually Changed: The Technical Shift
The core change was a scheduling decision. Prior to 2023, psilocybin was a Schedule 9 substance, meaning it had no established therapeutic use and was essentially prohibited except for limited research purposes . The TGA’s decision reclassified it to Schedule 8 for a specific use: treatment-resistant depression .
This means that for this single indication, psilocybin is now legally considered a medicine with a legitimate therapeutic use. However, a critical detail remains: there are currently no psilocybin products registered on the Australian Register of Therapeutic Goods (ARTG) . This means all legal psilocybin is an unapproved therapeutic good that the TGA has not evaluated for safety, quality, or efficacy in the same way as registered medicines.
The Critical Caveats: What It Does NOT Mean
It is essential to clarify what this change does not mean. The down-scheduling is not a general legalisation. For all other indications, psilocybin remains a Schedule 9 prohibited substance. It is not available for recreational use, general mental health treatment, or self-medication. The penalties for possession or supply outside the medical pathway remain severe.
Furthermore, the decision was not without controversy. Some experts, including those who contributed to an independent report commissioned by the TGA, have argued that the decision was premature . The TGA made a “delegate-only” decision without reference to its own expert committee, the Advisory Committee on Medicines Scheduling (ACMS) . Critics point to the limited and variable quality of evidence, with some clinical trial results no longer showing significance at 12-week follow-up . They also highlight unresolved issues around relapse, long-term safety, and the challenges of conducting effective clinical trials . Consequently, some clinicians and researchers believe the science is not yet robust enough for widespread clinical adoption .
What the Change Means for Patients in Practice
For patients, the practical reality is a highly restricted, multi-step process that is currently accessible to very few Australians.
Step 1: Eligibility
Only patients with treatment-resistant depression (TRD) are eligible. This means they must have failed to respond to multiple standard treatments. Psychiatrists must consider all TGA-approved treatment options before even considering psilocybin .
Step 2: Finding a Prescriber
Only psychiatrists registered with the Australian Health Practitioner Regulation Agency (AHPRA) and Fellows of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) can prescribe psilocybin . As of early 2024, only 9 individual psychiatrists had received approval to prescribe psilocybin or MDMA . This extremely limited number of prescribers is a major bottleneck.
Step 3: The Authorised Prescriber (AP) Pathway
The prescribing psychiatrist must apply to become an Authorised Prescriber. This requires developing a clinical treatment protocol and obtaining approval from a registered Human Research Ethics Committee (HREC) . Following this, they must seek and obtain TGA authorisation .
Step 4: The Treatment Setting
The TGA explicitly states that “protocols that allow patients to take these medicines home are not accepted under the AP scheme.” Treatment must occur in a medically supervised setting with established patient monitoring procedures. The psychiatrist must be present throughout the session .
Beyond the eligibility and authorisation process, significant barriers remain:
- Cost: The treatment is prohibitively expensive. The intensity of the therapy and the use of proprietary synthetic psilocybin (like COMP360) mean costs are likely to be very high, potentially exceeding $20,000 per course of treatment .
- Training: There are very few psychiatrists adequately trained to deliver this therapy, limiting availability .
- Ongoing Debate: The decision remains controversial in parts of the medical community, with some arguing the evidence is not yet sufficient for widespread clinical use .
A New Quality Standard: TGO 113
To address the quality of the psilocybin products used in this medical pathway, the TGA introduced a new quality standard called Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024 . This applies to both plant-derived and synthetic psilocybin. It sets requirements for identification, assay limits (80-120% for psilocybin), labelling, and purity . This ensures that any psilocybin product used in Australia meets minimum quality requirements. Manufacturers and suppliers have until early 2025 to comply .
Conclusion
The TGA’s down-scheduling of psilocybin is a landmark shift in drug policy. It officially recognises the therapeutic potential of psilocybin and creates a legal framework for its medical use. However, for Australian patients, this change does not translate into easy access. It remains a highly restricted, expensive, and controversial treatment available only to a very small number of patients with treatment-resistant depression, treated by a very small number of authorised psychiatrists in controlled medical settings. The clinical and regulatory landscape will likely evolve, but for now, the gap between the announcement and patient access is significant. This guide is for educational and research purposes only and does not constitute legal advice.